Courts Should Kill Trump's Pricey '2-for-1' Deregulation Order
![](https://cpr-assets.s3.amazonaws.com/images/SupCtColumns_wide.2e16d0ba.fill-280x130.jpg)
Courts Should Kill Trump's Pricey '2-for-1' Deregulation Order, op-ed by Dan Farber
Read PDF
Author(s): Daniel Farber
Joint Letter to OIRA re Guidance to Agencies on Implementation of 2-for-1 Deregulatory Executive Order
![](https://cpr-assets.s3.amazonaws.com/images/columnfeet_wide.2e16d0ba.fill-280x130.jpg)
Joint Letter to OIRA from 31 CPR Member Scholars and Staff re Guidance to Agencies on Implementation of 2-for-1 Deregulatory Executive Order
Read PDF
Federal Proposal Would Jeopardize Public Safety
![](https://cpr-assets.s3.amazonaws.com/images/WorkplaceAccident_wide.2eaa7a34.fill-280x130.jpg)
Federal Proposal Would Jeopardize Public Safety, op-ed by Thomas McGarity
Read PDF
Author(s): Thomas McGarity
Lisa Heinzerling's testimony before the Senate Commerce Committee on the importance of regulatory safeguards.
![](https://cpr-assets.s3.amazonaws.com/images/sunbeam-forest-wide.2e16d0ba.fill-280x130.jpg)
Lisa Heinzerling's February 1, 2017, testimony before the Senate Commerce Committee on the importance of regulatory safeguards.
Read PDF
Author(s): Lisa Heinzerling
Quietly Passed Act Favors Profits Over Health and Safety
![](https://cpr-assets.s3.amazonaws.com/images/columnfeet_wide.2e16d0ba.fill-280x130.jpg)
Quietly Passed Act Favors Profits Over Health and Safety, op-ed by Thomas McGarity
Read PDF
Author(s): Thomas McGarity
Beware Compounded Drugs -- Especially Under Trump’s FDA
![](https://cpr-assets.s3.amazonaws.com/images/PillsCloseUp.69b99768.fill-280x130.jpg)
Writing for The American Prospect, Rena Steinzor observes that a burgeoning and little-regulated private industry that specially mixes drugs at so-called compounding pharmacies poses a public-health hazard that the Trump administration will only make worse.
Read PDF
Author(s): Rena Steinzor